C WorldWide Group’s Neurocrine Biosciences NBIX Stock Holding History

C WorldWide Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.1M	Hold	125,000	–	–	0.51%	32
2026 Q1	$16.5M	Hold	125,000	–	–	0.35%	36
2025 Q4	$17.7M	Hold	125,000	–	–	0.31%	40
2025 Q3	$17.5M	Sell	125,000 -10,000	-7%	-$1.35M	0.27%	41
2025 Q2	$17M	Buy	135,000 +20,000	+17%	+$2.29M	0.23%	41
2025 Q1	$12.7M	Hold	115,000	–	–	0.16%	56
2024 Q4	$15.7M	Buy	115,000 +20,000	+21%	+$2.47M	0.19%	46
2024 Q3	$10.9M	Buy	95,000 +20,000	+27%	+$2.74M	0.11%	66
2024 Q2	$10.3M	Buy	+75,000	New	+$10.3M	0.11%	64

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

C WorldWide Group's NBIX Position: Q2 2026 in Review

C WorldWide Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 125,000 shares worth $21.1M. The position accounts for 0.51% of the portfolio, ranked #32.

C WorldWide Group first reported a position in NBIX in Q2 2024 and has held it in 9 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

C WorldWide Group held 125,000 shares of Neurocrine Biosciences worth $21.1M as of Q2 2026.
C WorldWide Group left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.51% of C WorldWide Group's portfolio in Q2 2026, its #32 holding.
C WorldWide Group first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 9 quarters since.
778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on C WorldWide Group's 13F filing for Q2 2026, filed 4 Aug 2026.